Introduction: 5-azacitidine (AZA) is DNA methyltransferase inhibitor molecules. Many of cancerous cells have disrupted epigenetics pattern. This fact leads to utilizing AZA as epigenetics modulator and an anti cancer drug. Cancerous cells like other live organism has been upgrade. One of the mechanisms that cells resist toxic substances is disposal of drugs. Here we analysis a subset of RNA-seq data from AZA treated mesenchymal stem cells. These cells upregulate lysosomes pathway which might have great role in disposal of cell debris to the medium. This finding is according the drug resistance features of AML cancerous cells which have not a functional LAMP2 gene. LAMP2 is key factor in loading the materials to lysosomes.
Methods: 8 subset of data, including 4 controls and 4 treated samples have been downloaded from SRA-NCBI. The subsets have been analysed by galaxy platform and the network and further analysis has been done by string package.
Results: It has been demonstrated that many pathways including developmental, autoimmune, apoptosis, necrosis and many more biological has been initiated and upregulated by azacitidine. However it has not been shown that this agent upregulate any drug resistance genes. In this meta analysis research, we find out Aza could upregulation of lysosomes pathways. This could be significant because many cancerous cells have immunity for some specific drug. This resistance in azacitidine has been seen in lamp2 deficient cell lines.
Conclusion: Based on bioinformatics and resistance of some cell lines, it could be pivotal to test the cancerous cells for any mutation in lysosomes related genes before subscription of anti-cancer drugs such as AZA, especially Lamp2.
Keywords: AZA, Cancer, DNA methyltransferase , methylation, Lamp2